文献速递癫痫神经重症与神经感染

难治性惊厥性癫痫持续状态二线抗癫痫药的Meta分析与成本效果

Meta-analysis and cost-effectiveness of second-line antiepileptic drugs for status epilepticus.
PubMed 文献 · Neurology · 2019-01-01

该研究基于24项研究、1185例癫痫持续状态(SE)发作,比较非苯二氮䓬类抗癫痫药(非BZD AEDs)治疗苯二氮䓬抵抗性惊厥性SE的成本与效果。结果显示苯巴比妥(PB)控制发作概率最高(0.8),但左乙拉西坦(LEV)最具成本效果(ICER $18.55/SS);苯妥英/磷苯妥英(PHT)在效果和成本效果上均不占优。

要点

  • PB控制发作概率最高(0.8),其次VPA(0.71)、拉考沙胺(0.66)、LEV(0.62)、PHT(0.53)。
  • LEV最具成本效果(ICER $18.55/SS),其次VPA($94.44/SS)、PB($847.22/SS)。
  • PHT在效果和成本效果上均不优于其他非BZD AEDs,证据不支持其优先地位。

核心结论

  • VPA和PB在控制苯二氮䓬抵抗性惊厥性SE方面比PHT更有效。
  • 非BZD AEDs的成本效果存在明显重叠,但现有证据不支持PHT在效果或成本效果上的优势。

研究设计与样本

  • 决策分析模型,效果数据来自系统综述与Meta分析,成本数据来自公开价格。
  • 纳入24项研究,共1185例SE发作。
  • 主要结局为每终止一次发作的成本($/SS),并进行了敏感性分析。

主要发现

  • PB控制发作概率为0.8(95%CI 0.69-0.88),VPA为0.71(95%CI 0.61-0.79),拉考沙胺为0.66(95%CI 0.51-0.79),LEV为0.62(95%CI 0.5-0.73),PHT为0.53(95%CI 0.39-0.67)。
  • 两两比较:PB优于PHT(p=0.002),VPA优于PHT(p=0.043),PB优于LEV(p=0.018)。
  • LEV的ICER为$18.55/SS,VPA为$94.44/SS,PB为$847.22/SS;PHT和拉考沙胺与其他选项相比不具成本效果。
  • 敏感性分析显示成本效果有明显重叠,但PHT始终不如LEV、VPA和PB具有成本效果。

临床怎么用

  • 对于苯二氮䓬抵抗性惊厥性SE,可优先考虑VPA或PB而非PHT,因二者控制发作概率更高。
  • 若关注成本效果,LEV和VPA是更具经济性的选择,PB虽效果概率最高但ICER较高。
  • 现有证据不支持将PHT作为优先的二线非BZD AED选择。

局限性

  • 原文未明确报告局限性,需谨慎解读模型假设和成本数据来源的适用性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Compare the cost and effectiveness of nonbenzodiazepine antiepileptic drugs (non-BZD AEDs) for treatment of BZD-resistant convulsive status epilepticus (SE). METHODS: Decision analysis model populated with effectiveness data from a systematic review and meta-analysis of the literature, and cost data from publicly available prices. The primary outcome was cost per seizure stopped ($/SS). Sensitivity analyses evaluated the robustness of the results across a wide variation of the input parameters. RESULTS: We included 24 studies with 1,185 SE episodes. The most effective non-BZD AED was phenobarbital (PB) with a probability of SS of 0.8 (95% confidence interval [CI]: 0.69-0.88), followed by valproate (VPA) (0.71 [95% CI: 0.61-0.79]), lacosamide (0.66 [95% CI: 0.51-0.79]), levetiracetam (LEV) (0.62 [95% CI: 0.5-0.73]), and phenytoin/fosphenytoin (PHT) (0.53 [95% CI: 0.39-0.67]). In pairwise comparisons, PB was more effective than PHT (p = 0.002), VPA was more effective than PHT (p = 0.043), and PB was more effective than LEV (p = 0.018). The most cost-effective non-BZD AED was LEV (incremental cost-effectiveness ratio [ICER]: $18.55/SS), followed by VPA (ICER: $94.44/SS), and lastly PB (ICER: $847.22/SS). PHT and lacosamide were not cost-effective compared to the other options. Sensitivity analyses showed marked overlap in cost-effectiveness, but PHT was consistently less cost-effective than LEV, VPA, and PB. CONCLUSION: VPA and PB were more effective than PHT for SE. There is substantial overlap in the cost-effectiveness of non-BZD AEDs for SE, but available evidence does not support the preeminence of PHT, neither in terms of effectiveness nor in terms of cost-effectiveness.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Sánchez Fernández I, Gaínza-Lein M, Lamb N, et al. Meta-analysis and cost-effectiveness of second-line antiepileptic drugs for status epilepticus. Neurology. 2019. PMID: 31068480. doi:10.1212/WNL.0000000000007503

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。